The pharmacokinetics of methadone in healthy subjects and opiate users

British Journal of Clinical Pharmacology

Volumn 44, Issue 4, 1997, Pages 325-334

  Wolff, K ^a   Rostami Hodjegan, A ^b   Shires, S ^c   Hay, A W M ^c   Feely, M ^d   Calvert, R ^d   Raistrick, D ^e   Tucker, G T ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

^e Leeds Addiction Unit   (United Kingdom)

Author keywords

Methadone; Opiate dependence; Pharmacokinetics; Population kinetics

Indexed keywords

METHADONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; METHADONE TREATMENT; NAUSEA; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; VERTIGO; VOMITING;

EID: 0030817232     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00591.x     Document Type: Article

References (50)

1. Wolff K, Hay AWM. Plasma methadone monitoring with methadone maintenance treatment. Drug Alcohol Dependence 1994; 36: 69-71.
2. Speiga R, Grabowski J, Silverman PB, Meisch RA. Human methadone self-administration: effect of dose and ratio requirements. Behavioural Pharmacol 1996; 7: 130-137.
3. Cairns A. Better understanding of body's handling of methadone is needed. Br Med J 1996; 313: 1479.
4. Nichole N. Naloxone infusion should have been started earlier. Br Med J 1996; 313: 1479.
5. Finfer S. Close observation in intensive careunit is required when naloxone infusion ends. Br Med J 1996; 313: 1480.
6. Horns WH, Rado M, Goldstein A. Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther 1975; 17: 636-649.
7. Tennant Jr. FS. Adequate plasma concentrations in some high dose methadone maintenance patients. Am J Psychiat 1987; 144: 1349-1350.
8. Bell J, Seres V, Bowron P, Lewis J, Batey R. The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther 1988; 43: 623-629.
9. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. Special communication. J Am Med Ass 1988; 260: 3025-3029.
10. Wolff K, Sanderson M, Hay AWM, Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem 1991; 37: 205-209.
11. Holmstrand J, Anggard E, Gunne LM. Methadone maintenance: Plasma levels and therapeutic outcome. Clin Pharmacol Ther 1978; 23: 175-180.
12. Loimer N, Schmid R. The use of plasma levels to optimise methadone maintenance treatment. Drug Alcohol Dependence 1992; 30: 241-246.
13. Kell MJ. Utilization of plasma and urine methadone concentrations to optimise treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addictive Diseases 1994; 13: 5-25.
14. Meisch RA, Stewart RB, Wang NS. Orally delivered methadone as reinforcer for rhesus monkeys: the relationship between drug concentration and choice. Pharmacol Biochem Behavior 1996; 54: 547-554.
15. Wolff K, Hay AWM, Raistrick, Calvert R. Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 1993; 44: 189-194.
16. Sawe J, Hansen J, Ginman J, et al. Patient controlled dose regime of methadone for chronic cancer pain. Br Med J 1991; 282: 771-773.
17. Schmidt N, Sittl R, Brune K, Geisslinger G. Rapid determination of methadone in plasma, cerebrospinal fluid, and urine by gas chromatography and its application to routine drug monitoring. Pharm Res 1993; 10: 441-144.
18. Plummer JL, Gourlay GK, Cousins C, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33: 313-322.
19. Inturrisi CE, Colburn WA. Pharmacokinetics of methadone. In Advances in Pain Research and Therapy, eds Foley KM, Inturrisi CE, New York: Raven Press, 1986; 191-199.
20. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392-401.
21. Bullingham RES, McQuay HJ, Porter EJB, Thomas D, Allen MC, Moore RA. Acute I.V. methadone kinetics in man: relationship to chronic studies. Br J Anaesth 1982; 54: 1271-1275.
22. Magora F, Chrubasik J, Damm D, Schulte-Monting J, Shir Y. Application for a new method for the measurement of plasma methadone levels to the use of epidural methadone for relief of postoperative pain. Anesth Analg 1987; 66: 1308-1311.
23. Gourlay GK, Wilson PR, Glynn CJ. Pharmacodynamics and pharmacokinetics of methadone in the pre-operative period. Anesthesiology 1982; 57: 458-467.
24. Meresaar U, Nilsson MI, Holmstrand J, Anggard E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol 1981; 20: 473-478.
25. Nilsson MI, Anggard E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: Adaptive changes during the inductive phase. Eur J Clin Pharmacol 1982; 22: 343-349.
26. Nilsson MI, Meresaar U, Anggard E. Clinical pharmacokinetics of methadone. Acta Anaesth Scand Suppl 1982; 74: 66-69.
27. De Vos JW, Geerlings PJ, Van Den Brink W, Ufkes JGR, Van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995; 48: 361-366.
28. Anggard E, Nilsson MI, Holmstrand J, Gunne LM. Pharmacokinetics of methadone maintenance: pulse labelling with deuterated methadone in the steady-state Eur J Clin Pharmacol 1979; 16: 53-57.
29. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13: 923-930.
30. Olsen GD, Wilson JE, Robertson GE. Respiratory and ventilatory effects of methadone in healthy women Clin Pharmacol Ther 1981; 29: 373-380.
31. Leeds Addiction Unit and Northern Regional Srug and Alcohol Service, Newcastle, Opioid Symptom Severity Assessment (SSA) Chart. 1991.
32. Yamaoka K, Nakagawa T, Uno T. Application of Akaiki's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharm 1976; 6: 165-175.
33. Armitage P, Berry G. Statistical Methods in Medical Research, Blackwell Scientific Publications, Oxford, 1987.
34. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. Clinical effect and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1977; 21: 147-157.
35. De Vos JW, Ufkes JGR, Van Brussel GHA, Van Den Brink W. Craving despite extremely high methadone dose. Drug Alcohol Dependence 1996; 40: 181-184.
36. Verebely K, Volavka J, Mulé S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975; 18: 180-190.
37. Knstensen K, Blemmer T, Angelo HR, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monitor 1996; 18: 221-227.
38. Olsen GD. Methadone binding to human plasma proteins. Clin Pharmacol Ther 1974; 14: 338-43.
39. Nilsson MI, Widerlof E, Meresaar U. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 1982; 22: 337-342.
40. Bellward GD, Warren PM, Howald W, Axelson JE, Abbott FS. Methadone maintenance. Effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther 1977; 22: 92-99.
41. Garrido MJ, Jiminez R, Gomez E, Calvo R. Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal. J Pharm Pharmacol 1996; 48: 281-284.
42. 1-acid glycoprotein. Clin Pharmacol Ther 1982; 32: 652-658.
43. 1-acid glycoprotein and serum protein binding of methadone in heroin addicts during withdrawal. Proc VI World Congress on Clinical Pharmacology and Therapeutics, Buenos Aires, Argentina, 1996; 174.
44. Thompson JW. Available opiates. In Opioids - use and abuse, Royal Society of Medicine Services International Congress and Symposium Series No. 107, eds Levy J, Budd K, London: Royal Society of Medicine Services Ltd, 1896: 9-20.
45. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol 1996; 42: 589-597.
46. Denson DD, Concilus RR, Warden G, Prithvi Raj P. Pharmacokinetics of continuous intravenous infusion of methadone in early post-burn patients. J Clin Pharmacol 1990; 30: 70-75.
47. Inturrisi CE, Verebely K. The levels of methadone in plasma during methadone maintenance. Clin Pharmacol Ther 1972; 13: 633-647.
48. Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, Baumann P. Replacement of (R)-methadone by a double dose of (R, S)-methadone in addicts: inter-individual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 1996; 50: 385-389.
49. Anggard E, Gunne LM, Holmstrand J, McMahon RE. Sandberg CG, Sullivan HR. Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 1975; 17: 258-266.
50. Nilsson MI, Gronbladh I, Wilderlov E, Anggard E. Pharmacokinetics of methadone in methadone maintenance treatment: Characterisation of therapeutic failures. Eur J Clin Pharmacol 1983; 25: 497-501.